UCLA medical school illegally used race in admissions, Department of Justice says – Image for illustrative purposes only (Image credits: Unsplash)
Los Angeles – The Department of Justice has concluded after a year-long review that the David Geffen School of Medicine at UCLA intentionally factored race into admissions decisions for the classes entering in 2023, 2024 and 2025. The finding comes as federal officials increase pressure on universities to align with the Supreme Court’s 2023 ban on race-conscious admissions. It also raises immediate questions about whether the school could face loss of federal funding or further legal action.
Why the Finding Matters Now
The ruling arrives amid broader federal scrutiny of medical school admissions across the country. Investigators determined that UCLA’s process gave preference to Black and Hispanic applicants over White and Asian American candidates with stronger academic records. Data cited in the letter of findings showed lower average GPAs and test scores among admitted students from the favored groups. This pattern, the department said, violated Title VI of the Civil Rights Act and the Equal Protection Clause. The development carries weight because medical schools train future physicians whose qualifications directly affect patient care. Any shift in how applicants are evaluated could influence the composition of incoming classes for years to come.
What the Investigation Uncovered
Federal reviewers examined internal documents and admissions data spanning three cycles. They found evidence that school leadership selected applicants in part to achieve specific racial balances. One application prompt invited students to discuss membership in a “marginalized group,” which the department viewed as a proxy for race. Admitted Black students in 2024 posted an average GPA of 3.72, compared with 3.84 for Asian American admits and 3.83 for White admits. Similar gaps appeared in standardized test scores. The department concluded these differences reflected the use of non-academic factors to meet diversity targets. UCLA’s medical school responded that its process remains “based on merit” and that it is reviewing the findings while committed to compliance with state and federal law.
Legal and Practical Context
California voters banned affirmative action in public university admissions in 1996. The 2023 Supreme Court decision extended that prohibition nationwide. Despite those rules, the Justice Department determined UCLA continued to weigh race directly. The school now faces two main paths: reach a voluntary agreement to change its practices or defend against potential enforcement action. Penalties could include restrictions on federal grants and contracts that support research and training programs.
| Key Finding | Supporting Detail | Remaining Uncertainty |
|---|---|---|
| Race used as factor | Lower academic metrics for preferred groups | Exact weight assigned to race in each decision |
| Proxy questions | Marginalized-group essay prompt | Whether prompt will be revised or removed |
| Funding risk | Title VI violation cited | Whether negotiations will avert cuts |
What Matters Now
The letter of findings marks the first formal federal determination against a medical school under the current administration’s enforcement approach. Other institutions under parallel reviews will watch closely for the outcome at UCLA. Any changes to admissions criteria will unfold over the next application cycle. Observers note that medical schools must still consider how an applicant’s background shapes their perspective, provided the evaluation stays race-neutral. The precise boundary between permissible context and impermissible preference remains the central point of ongoing debate. The department’s action underscores that compliance with the Supreme Court ruling is no longer optional for institutions receiving federal support. How UCLA and similar schools adjust will shape both the makeup of future physician classes and the legal standards applied to higher education more broadly.
